World-first trial takes aim at deadly silicosis
New hope is on the horizon for silicosis sufferers with Melbourne experts set to embark on a world-first trial designed to halt progression of the deadly lung disease.
www.alfredhealth.org.auHere are the latest publicly reported updates I can summarize now.
Brief answer
- There is ongoing global reporting of silicosis research and clinical trials aiming to halt progression or treat the disease, with notable activity in Australia in 2025 and continuing advocacy and monitoring by health organizations.
Key updates and sources
- Australia: Melbourne researchers at The Alfred launched or announced a world-first trial in 2025 to test a targeted anti-inflammatory drug to halt progression of silicosis. The trial is supported by a multi-year funding commitment and reflects ongoing efforts to find disease-modifying therapies, given that no approved treatments exist yet for silicosis. This aligns with earlier reporting on silicosis research funding in Australia, including MRFF-supported projects exploring inflammation, biomarkers, and potential repurposing of existing drugs.[2][3]
- Australia: Additional reporting around silicosis research funding and early-stage studies highlights interest in identifying biomarkers of disease severity and progression, and evaluating imaging strategies (e.g., high-resolution CT vs chest X-ray, ultralow-dose CT) to screen for early silicosis and monitor progression.[3]
- Global context: The American Lung Association and other health organizations describe silicosis as an incurable but preventable lung disease caused by inhaling silica dust, underscoring prevention as the primary strategy and noting the absence of universally curative therapies in many settings.[5]
- Related developments (contextual): News coverage in 2025-2026 variously discuss AI-assisted detection and new pharmacological approaches in research pipelines, reflecting a broader push to both prevent exposure and identify disease-modifying strategies as the field evolves.[9]
- Broader human-rights and regulatory angles: Several outlets discuss worker rights, occupational safety improvements, and regulatory responses to silicosis in different jurisdictions, highlighting ongoing efforts to reduce exposure and improve compensation and protection for workers at risk.[6][10]
What this means for you
- If you’re assessing risk or monitoring for updates in your region (Paris/Île-de-France): silicosis remains primarily a workplace health issue in industries with silica exposure. Updates tend to center on prevention, early detection via imaging, and research into treatments, with Australia currently among the most active reporting on clinical trials and funding for potential therapies.[2][3][5]
- For patients or workers: current standard care focuses on managing symptoms and preventing further exposure; disease-modifying therapies are under investigation in trials, and participation may be possible in some centers depending on eligibility and location.[5][2]
Would you like me to:
- Narrow this to developments specific to Europe or France, including any local studies or regulatory updates?
- Pull recent press releases or official health agency statements from 2026?
- Summarize what doctors and employers can do now to reduce silicosis risk in high-exposure industries?